1. Home
  2. ARGX vs GRMN Comparison

ARGX vs GRMN Comparison

Compare ARGX & GRMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARGX
  • GRMN
  • Stock Information
  • Founded
  • ARGX 2008
  • GRMN 1990
  • Country
  • ARGX Netherlands
  • GRMN Switzerland
  • Employees
  • ARGX N/A
  • GRMN N/A
  • Industry
  • ARGX Biotechnology: Biological Products (No Diagnostic Substances)
  • GRMN Industrial Machinery/Components
  • Sector
  • ARGX Health Care
  • GRMN Industrials
  • Exchange
  • ARGX Nasdaq
  • GRMN Nasdaq
  • Market Cap
  • ARGX 35.2B
  • GRMN 40.8B
  • IPO Year
  • ARGX 2017
  • GRMN 2000
  • Fundamental
  • Price
  • ARGX $589.51
  • GRMN $209.72
  • Analyst Decision
  • ARGX Strong Buy
  • GRMN Hold
  • Analyst Count
  • ARGX 21
  • GRMN 6
  • Target Price
  • ARGX $619.79
  • GRMN $162.17
  • AVG Volume (30 Days)
  • ARGX 302.1K
  • GRMN 1.1M
  • Earning Date
  • ARGX 10-31-2024
  • GRMN 10-30-2024
  • Dividend Yield
  • ARGX N/A
  • GRMN 1.46%
  • EPS Growth
  • ARGX N/A
  • GRMN 45.02
  • EPS
  • ARGX N/A
  • GRMN 7.86
  • Revenue
  • ARGX $1,908,659,000.00
  • GRMN $5,956,843,000.00
  • Revenue This Year
  • ARGX $61.99
  • GRMN $19.73
  • Revenue Next Year
  • ARGX $42.48
  • GRMN $8.43
  • P/E Ratio
  • ARGX N/A
  • GRMN $26.14
  • Revenue Growth
  • ARGX 85.56
  • GRMN 17.91
  • 52 Week Low
  • ARGX $327.73
  • GRMN $119.15
  • 52 Week High
  • ARGX $611.22
  • GRMN $215.55
  • Technical
  • Relative Strength Index (RSI)
  • ARGX 56.12
  • GRMN 66.10
  • Support Level
  • ARGX $558.15
  • GRMN $204.16
  • Resistance Level
  • ARGX $592.29
  • GRMN $215.55
  • Average True Range (ATR)
  • ARGX 12.42
  • GRMN 3.20
  • MACD
  • ARGX -2.11
  • GRMN -0.83
  • Stochastic Oscillator
  • ARGX 56.76
  • GRMN 59.29

About ARGX argenx SE

Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.

About GRMN Garmin Ltd. (Switzerland)

Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.

Share on Social Networks: